Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $45.46 USD
Change Today +0.35 / 0.78%
Volume 796.8K
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

impax laboratories inc (IPXL) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $52.10
52 Week Low
08/4/14 - $22.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

impax laboratories inc (IPXL) Related Businessweek News

No Related Businessweek News Found

impax laboratories inc (IPXL) Details

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinson’s disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.

1,061 Employees
Last Reported Date: 02/26/15
Founded in 1993

impax laboratories inc (IPXL) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $552.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $446.2K
President of Impax Pharmaceuticals
Total Annual Compensation: $515.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $484.2K
Senior Vice President of Technical Operations
Total Annual Compensation: $419.6K
Compensation as of Fiscal Year 2014.

impax laboratories inc (IPXL) Key Developments

Impax Laboratories Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Impax Laboratories Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $143,096,000 against $118,718,000 a year ago. This increase is the result of higher sales of the company's existing products and revenue from approximately three weeks of sales of products acquired in the company's acquisition of Tower Holdings Inc. and Lineage Therapeutics Inc. on March 9, 2015. Loss from operations was $6,848,000 against income from operations of $8,231,000 a year ago. Loss before income taxes was $10,705,000 against $8,630,000 a year ago. Net loss was $6,333,000 or $0.09 per basic and diluted share against net income of $6,425,000 or $0.09 per basic and diluted share a year ago. The decrease in EPS is primarily attributable to unfavorable product sales mix and the timing of certain events as noted above. In addition, the first quarter 2015 results include approximately $8.5 million of expenses or $0.07 per diluted share associated with the launch of RYTARY and interest expense in connection with the Tower acquisition, for which there were no comparable amounts in the prior year period. Net cash provided by operating activities was $23,657,000 against net cash used in operating activities of $17,076,000 a year ago. Purchases of property, plant and equipment was $4,223,000 against $9,782,000 a year ago. Adjusted net income was $6,239,000 or $0.09 per diluted share against $16,481,000 or $0.24 per diluted share a year ago. LBITDA was $858,000 against EBITDA of $13,892,000 a year ago. Adjusted EBITDA was $23,987,000 against $34,779,000 a year ago. The company's full year 2015 financial guidance remains unchanged. The company's full year 2015 estimates are based on management's current belief about prescription trends, pricing levels, inventory levels, and the anticipated timing of future product launches and events. The company's estimates exclude the impact from any products for which the company has not yet received approval from the U.S. Food and Drug Administration. Adjusted gross margins as a percent of total revenue are expected to be in the mid 50% range. Capital expenditures of approximately $45 million to $50 million. Effective tax rate of approximately 34% to 36% on a GAAP basis, which assumes that the U.S. R&D tax credit is renewed for 2015. The R&D tax credit expired on December 31, 2014. The company anticipates that its non-GAAP effective tax rate may experience volatility as the company's tax benefits may be high compared to the company's operating income or loss.

Impax Laboratories Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:00 AM

Impax Laboratories Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:00 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Bryan M. Reasons, Chief Financial Officer and Senior Vice President of Finance, Michael J. Nestor, President of Impax Pharmaceuticals.

Impax Laboratories, Inc. Announces Executive Appointments

Impax Laboratories Inc. announced that it has filled two key executive leadership roles, appointing Donna M. Hughes, as Senior Vice President, Human Resources and Deborah M. Penza, as Senior Vice President, Chief Compliance Officer. Both Ms. Hughes and Ms. Penza will report to Impax's President and Chief Executive Officer, Fred Wilkinson. Ms. Hughes, who has over 20 years of legal and human resources experience, will oversee all of Impax's human resource functions. She joins Impax from Actavis, where she was Vice President, Labor and Employment, and a member of Actavis' Global Leadership Team and Human Resources Leadership Team. Ms. Hughes was responsible for the management of all labor and employment law matters company-wide, including employment litigation, benefits, immigration, acquisition due diligence, post-merger integration, and global human resources issues. Ms. Penza has over 20 years of experience as both a consultant and a compliance professional implementing and operating compliance programs in the healthcare industry. She will be responsible for the development, implementation and oversight of Impax's corporate compliance program. Ms. Penza joins Impax from Actavis, where she was Chief Compliance Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPXL:US $45.46 USD +0.35

IPXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPXL.
View Industry Companies

Industry Analysis


Industry Average

Valuation IPXL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPAX LABORATORIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at